



## APPLICATION FOR RESEARCH FUNDING

**Closing Date: 31 May 2022**

The Granulosa Cell Tumour Research Foundation (GCTRF) strives to advance research in the treatment of granulosa cell tumour of the ovary (GCT). The Foundation is a charitable patient advocacy group and conducts a range of activities including:

- Fostering focused research on treatment of GCT
- Educating GCT patients on the nature of the disease and providing them with information they can share with their medical team
- Facilitating networking of GCT patients to reduce the isolation felt by patients of a rare disease.

The Foundation is open to receiving proposals for funding of research that could have clinical impact in the near term. Awards are made following competitive evaluation by our science advisory panel, have a performance period of up to two years and carry a maximum value of \$80,000 USD.

In preparing your proposal the following points should be noted:

- The value of any grant is limited to \$80,000 USD.
- Proposed research should address both juvenile GCT and adult GCT.
- The Foundation does not fund equipment, including computers.
- The Foundation does not fund travel.
- Funds provided are considered an award, therefore institutional overhead and indirect costs will not be funded.
- Any collaborators or co-investigators must provide signed confirmation that they are aware of, and agree to participate in, the research.
- Applications will be evaluated in accordance with a modified NCI scoring system.
- The Foundation encourages publication or presentation of findings it has funded, in full or in part, and award recipients are required to acknowledge funding support by the Granulosa Cell Tumour Research Foundation.

All researchers are welcome to apply with no limitation on where the research is conducted.

Proposals should be 4 pages or less (exclusive of references and 1 page of figures) and address all stated issues (next page). Applications are to be electronically transmitted to our Grants Administrator via email ([grants@gctrf.org](mailto:grants@gctrf.org)). Deadline for submission of applications is 11:59 p.m. Pacific Daylight Savings Time (PDT) 31 May 2022. All applications will be evaluated by our multi-disciplinary science advisory panel and scored in accordance with a modified NCI scoring system.

A 1-page "letter of intent to submit" should be sent to [grants@gctrf.org](mailto:grants@gctrf.org) by 11:59 p.m. PDT 30 April 2022. The letter should include a working title, name of the principal investigator, a brief layperson summary of the intended project, and a statement of how the project could impact clinical effectiveness in treating GCT.

For more information, email the Grants Administrator or visit our website.

Proposals should include the following information as appropriate.

**Title of Project**

**Contact details**

Principal Investigator(s):

Co-investigator(s) and Collaborator(s):

**Project Summary**

**Project Detail**

- **Background**
- **Aims**
- **Methods**
- **End Points**
- **Significance**

**Layperson Summary**

If funded, this summary may be used in donor communications and/or on our website.

**Ethical Approval (Required/Obtained)**

**Proposed Budget**

Breakout of project expenses in categories of salary, reagents, other direct costs (itemised).

If the proposed project requires additional funding from other sources, identify the other source and whether funding has already been approved. If additional funding is required but not yet approved, identify what aims and endpoints will be achieved if this were to be the sole funding.

**Location of Research**

**Proposed Knowledge Translation Plan**

**Signatures**

**Principal Investigator:**

**Institutional Approval**

Position:

Name:

Signature: